Head-to-head · WeighScore
HealthRX vs MyFastRx
By GLP-1 ScorecardUpdated
Score comparison
HealthRX has the higher recorded score — 77.5/100 to 67.6/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.
Before you choose
Before comparing the headline prices, the HealthRX review and the MyFastRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, HealthRX vs NexLife and MyFastRx vs Ondra Health compare each of them with another graded program, and the list of alternatives to HealthRX ranks the programs closest to HealthRX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HealthRX | MyFastRx |
|---|---|---|
| WeighScore | 77.5/100 | 67.6/100 |
| Grade | C+ | C |
| Site position | #34 | #174 |
| Semaglutide | $39 first month, then $125/month on a 3-month plan ($115 on 6 months, $97 on 12); month to month $109 first month, then $139/month | $169/mo |
| Tirzepatide | $39 first month, then $219/month on a 3-month plan ($179 on 6 months, $159 on 12); month to month $109 first month, then $239/month | $249/mo |
| Coverage | All 50 states claimed; subject to clinical eligibility | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- First payment and recurring monthly charge shown together for every plan
- Medication if prescribed, review, instructions and overnight shipping included; no separate GLP-1 membership fee stated
- A month-to-month option carries no minimum term
- Full refund promised if clinical approval is declined
What to consider
- On 3-, 6- and 12-month plans the remaining monthly payments stay due after an early cancellation
- Assigned medical practice and dispensing pharmacy not named on reviewed public pages
- Refund promises for unshipped doses need reconciliation with restrictions after dispensing
- Injection supplies, clinical response time and monitoring cadence unconfirmed
Strengths
- Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
- LegitScript certified
- All doses priced the same — no cost escalation as you titrate up
- First-month promo discount lowers the trial barrier
What to consider
- States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
- Corporate address and medical director not published
- Pharmacy partner not named — only 'state-licensed pharmacies'
- Cash-pay only — no insurance billing
- Bundle savings require a large upfront commitment (12 months billed at once)
Featured provider
HealthRX
Factor scores not reassessed.HealthRX scores 77.5/100 (C+). HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.